Patient: Page 3
-
Q&A
With OTC birth control approved, access battles have just begun
Perrigo received the first FDA approval for an OTC birth control pill. Now, its global VP of women’s health says the company is working on the next challenge — affordability.
By Karissa Waddick • July 26, 2023 -
Threads joins the social media fray. Hereās what it means for pharma marketers.
Meta’s new platform is drawing Twitter comparisons and could hold potential for pharma marketers in patient and HCP communication.
By Karissa Waddick • July 18, 2023 -
Explore the Trendlineā
Stock via Getty ImagesTrendlineWomen's health
As women’s health investments explode, major opportunities for growth remain.
By PharmaVoice staff -
DCTs create fresh privacy challenges for review boards. Now there are guidelines.
A new toolkit developed by industry stakeholders paves the way for faster reviews.
By Kelly Bilodeau • July 17, 2023 -
The stories youāve read the most in 2023 (so far)
From staff shortages to presidential candidates and the M&A outlook, here are our most-read stories from the first half of the year.
By PharmaVoice Staff • July 3, 2023 -
A unique study on COVID shows how machine learning can help personalize medicine
Based on real-world data from patients in China, researchers were able to pinpoint factors that led to recurring infections — and which drug combos helped.
By Kelly Bilodeau • June 26, 2023 -
Profile
Is America ready for a new kind of opioid?
Tris Pharma’s CEO is “betting the company” on a pain reliever with the power of an opioid and a lower chance of addiction.
By Alexandra Pecci • June 12, 2023 -
Sponsored by Adheris Health
First-party data: The answer to a cookie-less future
While online cookies revolutionized online advertising and are a big part of a $600 billion dollar industry, targeting consumer/patient behavior is about to get much more difficult
By Heather Campbell, VP Marketing, Adheris Health • June 12, 2023 -
Why cancer could be the ideal realm for psychedelic treatments
The CEO of Sunstone Therapies said the results of a recent trial testing psilocybin in cancer patients with depression were “remarkable.”
By Meagan Parrish • June 9, 2023 -
Podcast
Woman of the Week: Marinus Pharmaceuticalsā Christy Shafer
The chief commercial officer shares how the company “beat the odds” to bring a rare disease drug to market.
By Taren Grom • June 7, 2023 -
Opinion
A key to āwinningā in todayās market ā and other trends pharma leaders are tracking
Healthcare pros share the market drivers they believe are having the biggest impact on the industry.
By Taren Grom • June 2, 2023 -
CVS is exiting clinical trials. Does this spell trouble for retail-based research?
Walgreens leaders are not deterred and hope to fill the holes left behind by the pharmacy giant.
By Kelly Bilodeau • May 30, 2023 -
Amid surging Duchenne market, Capricor touts potential ābackboneā therapy of the space
The company's CEO on the vital role its late-stage candidate could play in the lives of DMD patients.
By Kelly Bilodeau • May 22, 2023 -
Podcast
Woman of the Week: Genentechās Veronica Sandoval
How the Genentech diversity exec is using ‘three Ms’ to reduce health disparities and improve access for under-supported communities.
By Taren Grom • May 17, 2023 -
Podcast
Woman of the Week: Reneo Pharmaceuticalsā Ashley Hall
After ushering a blockbuster to market, the chief development officer is channeling her experience into the rare disease space.
By Taren Grom • May 10, 2023 -
Q&A
AbbVieās Christopher Boone on RWEās potential ā and its āprofound ethical dilemmasā
With decades of experience in public health, Boone is leveraging RWE to move the needle within clinical development.
By Taren Grom • May 10, 2023 -
Profile
This āhot-bloodedā CEO is aiming to transform the way burn victims heal
Cutiss CEO Daniela Marino is funneling her bold personality and expertise in regenerative medicine into a startup developing bioengineered skin grafts.
By Alexandra Pecci • May 9, 2023 -
Insulin prices have dropped ā will Civica still be a disrupter in the field?
The nonprofit generics maker still sees a need for low-cost insulin despite recent moves by major drugmakers to slash the prices of their popular products.
By Karissa Waddick • May 8, 2023 -
Podcast
Woman of the Week: Jazz Pharmaceuticalsā Neena Patil
Patil’s dual interests in healthcare and law are at the intersection of her C-suite role.
By Taren Grom • May 3, 2023 -
Scientists could finally be closing in on a āpillā for men
Drug developers have tried — and failed — to create a male contraceptive for decades. Now, one group of scientists might be on the verge of success.
By Kelly Bilodeau • April 26, 2023 -
Podcast
Woman of the Week: Brii Biosciencesā Ellee de Groot
A chemical engineer by training, Brii’s chief technology officer is applying her experience to solve research problems from the clinic to commercial development.
By Taren Grom • April 19, 2023 -
Patient influencers are here to stay ā where are the regulations?
As social media health influencers enter the world of pharma advertising, experts warn that more guardrails are needed to protect the industry and patients.
By Karissa Waddick • April 17, 2023 -
Podcast
Woman of the Week: uMotifās Julia Lakeland
The chief product officer’s work in transforming clinical trial technology is driven by people.
By Taren Grom • April 12, 2023 -
Whatās pharma doing wrong to improve trial diversity? āEverythingā
Pharma’s missing the mark when it comes to recruiting Black patients, and Ricki Fairley, CEO of The Black Breast Cancer Alliance, reveals what’s needed.
By Karissa Waddick • April 12, 2023 -
Where one unicorn struggled, another biotech is aiming for a diabetes win
Intarcia looked poised to break into a lucrative diabetes implant market but has been dogged by safety issues — now Vivani thinks it’s found a way to succeed.
By Kelly Bilodeau • April 10, 2023 -
Sponsored by GoodRx
GoodRx Health is the one-stop-shop for patients ā and marketers
Optimize patient conversion through a single platform with GoodRx: the one-stop-shop for patients — and marketers.
April 10, 2023